HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $36 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a price target of $36.
May 15, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Pliant Therapeutics and maintained a price target of $36, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $36 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100